Zarebski Adrian, Velu Chinavenmeni S, Baktula Avinash M, Bourdeau Tristan, Horman Shane R, Basu Sudeep, Bertolone Salvatore J, Horwitz Marshal, Hildeman David A, Trent John O, Grimes H Leighton
Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Immunity. 2008 Mar;28(3):370-80. doi: 10.1016/j.immuni.2007.12.020. Epub 2008 Mar 6.
Severe congenital neutropenia (SCN) is characterized by a deficiency of mature neutrophils, leading to recurrent bacterial and fungal infections. Although mutations in Elastase-2, neutrophil (ELA2) predominate in human SCN, mutation of Ela2 in mice does not recapitulate SCN. The growth factor independent-1 (GFI1) transcription factor regulates ELA2. Mutations in GFI1 are associated with human SCN, and genetic deletion of Gfi1 results in murine neutropenia. We examined whether human SCN-associated GFI1N382S mutant proteins are causal in SCN and found that GFI1 functions as a rate-limiting granulopoietic molecular switch. The N382S mutation inhibited GFI1 DNA binding and resulted in a dominant-negative block to murine granulopoiesis. Moreover, Gfi1N382S selectively derepressed the monopoietic cytokine CSF1 and its receptor. Gfi1N382S-expressing Csf1-/- cells formed neutrophils. These results reveal a common transcriptional program that underlies both human and murine myelopoiesis, and that is central to the pathogenesis of SCN associated with mutations in GFI1. This shared transcriptional pathway may provide new avenues for understanding SCN caused by mutations in other genes and for clinical intervention into human neutropenias.
严重先天性中性粒细胞减少症(SCN)的特征是成熟中性粒细胞缺乏,导致反复发生细菌和真菌感染。虽然弹性蛋白酶2(ELA2)、中性粒细胞中的突变在人类SCN中占主导,但小鼠中的Ela2突变并不能重现SCN。生长因子独立1(GFI1)转录因子调节ELA2。GFI1中的突变与人类SCN相关,Gfi1的基因缺失导致小鼠中性粒细胞减少。我们研究了人类SCN相关的GFI1N382S突变蛋白在SCN中是否具有致病性,发现GFI1作为一种限速粒细胞生成分子开关发挥作用。N382S突变抑制了GFI1与DNA的结合,并导致对小鼠粒细胞生成的显性负性阻断。此外,Gfi1N382S选择性地解除了对单核细胞生成细胞因子CSF1及其受体的抑制。表达Gfi1N382S的Csf1-/-细胞形成了中性粒细胞。这些结果揭示了人类和小鼠骨髓生成共同的转录程序,这是与GFI1突变相关的SCN发病机制的核心。这种共享的转录途径可能为理解由其他基因突变引起的SCN以及对人类中性粒细胞减少症的临床干预提供新的途径。